Loading clinical trials...
Loading clinical trials...
A Phase I Study of Premetrexed (Alimta) and Carboplatin and Radiation Therapy in Patients With Inoperable Non Small Cell Lung Cancer.
To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer
To determine the maximal tolerated dose (MTD) and toxicities of Pemetrexed (Alimta) when administered concurrently with carboplatin and thoracic radiation therapy. To determine, qualitatively, the occurrence of local tumor responses identified with this regimen.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Start Date
April 1, 2006
Primary Completion Date
August 1, 2009
Completion Date
October 1, 2009
Last Updated
May 2, 2025
18
ACTUAL participants
Premetrexed (Alimta)
DRUG
Carboplatin
DRUG
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions